SOPs/Instructions for Authors and templates for ESMO eUpdates
ESMO Guidelines Committee, January 2020

An electronic update (eUpdate) will be produced in the following instances:

- When important breakthroughs need to be rapidly communicated.
- When only few updates are needed for a Clinical Practice Guideline (CPG) instead of producing a revised version.
- When a Magnitude of Clinical Benefit Scale (ESMO-MCBS) score has been produced by the MCBS Working Group for a new therapy or a new indication of existing therapy, in the context of the relevant CPG.

Production of an eUpdate will be proposed by an author, Subject Editor (SE) or GLC Steering Committee (GLC-SC) member and approved by the GLC.

Drafting of the eUpdate is done by the SE and/or CPG coordinating author, reviewed by both and approved by the GLC (see template below).

When the eUpdate refers to an ESMO-MCBS score of a new therapy/indication approved by the European Medicines Agency (EMA), the identification of new EMA approvals is done by the MCBS Working Group, who calculates the ESMO-MCBS score. The score is reviewed and approved by the GLC. The eUpdate, including an MCBS table if applicable, is then drafted by the SE and/or CPG coordinating author and approved by the GLC.

For Guideline eUpdates, in case of disagreement, arbitration is performed by the GLC Chair and when necessary, by the GLC-SC. For MCBS Guideline eUpdates, arbitration is performed by the MCBS WG Chair with the GLC Chair and, when necessary, by the President’s Council.

The eUpdate is published online linked to the respective Guideline page on esmo.org and is also promoted on OncologyPRO.

Any eUpdate that is contemplated for integration into a Living Guideline will also be reviewed by two ESMO Faculty members or other experts.
Clinical Practice Guidelines
This update refers to the CPG title, CPG authors, CPG reference (Annals of Oncology)

Section
Title of the CPG section to which the update applies

Text update
Background text describing the reasons for update and data

Recommendation
Guidelines recommendation, including Level of Evidence and Grade of Recommendation
ESMO-MCBS table for new therapies/indications in XXX

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Disease setting</th>
<th>Trial</th>
<th>Control</th>
<th>Absolute survival gain</th>
<th>HR (95% CI)</th>
<th>QoL/toxicity</th>
<th>ESMO-MCBS score[^b]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Describe the new therapy</td>
<td>Describe the disease setting. Specify (Neo)adjuvant or Advanced</td>
<td>Name [1] Phase of trial NCT number</td>
<td>Describe the control arm</td>
<td>Median, in months (state OS, PFS or both)</td>
<td>Median and 95% CI</td>
<td>Improved or Deteriorated or Similar or Not Available</td>
<td>Score X (Form X)</td>
</tr>
</tbody>
</table>

[^a]: EMA approvals since January 2016.
[^b]: ESMO-MCBS version 1.1 [2]. The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee.

CI, confidence interval; EMA, European Medicines Agency; ESMO-MCBS, ESMO-Magnitude of Clinical Benefit Scale; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; QoL, quality of life.

**References**
1. Pivotal trial reference.